Basal cell, squamous cell and melanoma histories compared

"Skin cancer" is three different conversations in underwriting. A basal cell carcinoma removed in a dermatologist's office, a squamous cell carcinoma with a pathology report that mentions depth, and a melanoma staged by thickness are not treated as one thing, and an application that lumps them together can mislead both the applicant and the insurer. This post compares the three by what they are, what the records show, how follow-up matters and what recurrence does to the picture.

It does not quote ratings or waiting periods. Insurers publish none of this for the public, their guidelines differ and they change. What it can do is explain the reasoning so you know what your own records will say and which questions to prepare for.

Why the three types are not treated alike

An underwriter is estimating one thing: the chance that the disease shortens your life during the policy. For that purpose the three common skin cancers behave very differently.

• Basal cell carcinoma arises in the skin's lowest layer of cells. It is the most common skin cancer and it grows locally. It rarely spreads to other parts of the body, which is why it is often removed in an office procedure and why many insurers treat it as a minor item.
• Squamous cell carcinoma arises in the flat cells of the upper layers. It is also usually found early and cured by removal, but it is more likely than basal cell to spread, particularly when it is large, deep, in certain locations or in a person whose immune system is suppressed.
• Melanoma arises in the pigment-producing cells. It is less common than the other two, but it is the type that can spread to lymph nodes and organs. Its outlook depends strongly on how thick it was when removed and whether it had spread.

These are general descriptions of how the diseases behave. A doctor, not an insurer, decides what applies to any person. But they explain why the same word, "skin cancer," can produce a shrug from one underwriter and a long file review from another.

A side-by-side comparison

The last row describes tendencies, not promises. Companies differ widely in how they handle each, and the same company may handle an early melanoma differently from one that had reached the lymph nodes.

What the pathology report tells an underwriter

The pathology report is the document that turns "skin cancer" into a specific diagnosis. If an underwriter requests an attending physician statement, this is often the first thing they look for, and you can ask your dermatologist's office for a copy before you apply.

What to look for in each:

Basal cell. The report names the subtype and states whether the edges of the removed tissue are free of tumor ("clear margins"). A clear margin means the doctor removed all visible cancer. If margins were not clear, a re-excision is normally done, and the second report matters.

Squamous cell. The report adds how abnormal the cells look, how deep the cancer went, and whether it involved nerves. Deeper, poorly differentiated or nerve-involving tumors are treated as higher risk by doctors, and underwriters tend to follow.

Melanoma. The report is the most detailed. Thickness (often called Breslow thickness) is measured in millimeters and is the single most important number. Other items are whether the surface was ulcerated, how actively the cells were dividing, whether the margins were clear, and whether a sentinel lymph node biopsy was done and what it showed. A melanoma confined to the top layer of skin (often called in situ or stage 0) is a different file from one that had grown deeper or reached a node.

If you are given a copy of any of these reports, read the diagnosis line and the margin line first. Those are the two places an application question will point.

Follow-up exams and what they show

Skin cancer is not a one-and-done diagnosis for many people. After treatment, a dermatologist typically checks the skin on a schedule the doctor sets, which varies with the type and risk. Those notes become a second layer of evidence.

An underwriter reading follow-up notes is looking for:

• Regularity. Exams happening as advised suggest ongoing surveillance, which insurers view favorably.
• Findings. "No suspicious lesions" repeated over several visits builds a record of stability. New lesions are not a surprise for people prone to skin cancer; what matters is whether they are the same low-risk type.
• Escalation. A shift from office removals to larger surgery, referral to a specialist or imaging suggests something more serious.

For melanoma, higher stages may involve imaging at intervals, and the results become part of the file. Clean scans over time are what allow an underwriter to move from "too recent" to a decision.

Recurrence: same site versus a new spot

Recurrence is two questions that get blurred together.

1. Local recurrence means the same cancer returned where it was removed. It suggests the first treatment did not remove everything and is a stronger negative signal.
2. A new primary means a separate skin cancer elsewhere. For basal and squamous cell cancers, new lesions are common in people with a history of sun damage and are not usually read as treatment failure. For melanoma, a second primary is taken seriously because a person who has had one is at higher risk of another.

An underwriter distinguishes the two by looking at locations and dates in the records. If your history includes several small basal cell cancers over ten years, the list of removal dates and sites tells a story about a skin type and exposure, not about an advancing disease. That is worth knowing, and it is also why the clearest summary you can give an insurer is a dated list rather than "I've had a few."

Another distinction is precancerous spots. Actinic keratoses, rough patches that can develop into squamous cell cancer, and atypical (dysplastic) moles are common findings and are treated as skin conditions rather than cancers. Check how the application is worded before listing them: it matters whether the question asks about cancer or about any abnormal growth.

Three illustrative histories

These are invented to show the reasoning. They are not quotes and do not predict any insurer's decision.

Case 1, a basal cell cancer. Say Dana, 42, had a small basal cell carcinoma removed from her shoulder three years ago with clear margins. Her dermatologist sees her once a year and has found nothing since. Her record is two pathology reports and annual skin check notes. The likely underwriting questions are the date, the treatment and the follow-up. Many insurers treat a healed, completely removed basal cell cancer as a minor item, and some do not ask about it separately at all.

Case 2, a squamous cell cancer. Say Luis, 55, had a squamous cell carcinoma removed from his lower lip two years ago. The report notes a moderately differentiated tumor with clear margins and no nerve involvement. He now has checks every six months. The underwriter will ask about location and depth, because lip lesions are considered higher risk than some other sites, and will want the follow-up notes. The more they confirm a clean surgical result and regular exams, the easier the decision.

Case 3, a melanoma. Say Priya, 38, had a thin melanoma removed six years ago and a sentinel node biopsy that was negative. She has had regular skin checks since, with no recurrence. Her file is detailed: thickness, ulceration status, margins, node result and six years of clean exams. The underwriter's questions concern stage and time. A thin, early-stage melanoma with years of clean follow-up is a very different file from a thicker one with a positive node, and insurers are likely to ask for both the original pathology and recent notes. Her wait for the best offers may be longer than Dana's, but she has a complete file to show.

The common thread: each person is best served by dated records, not descriptions.

Time since treatment, and other things that change the reading

Time is the quiet variable in all three. A basal cell cancer removed last month is a different file from one removed ten years ago with annual clean exams, simply because the record has had time to show whether anything came back. For melanoma, where the disease can return years after treatment, underwriters generally want a longer clean record, and the stage at diagnosis decides how long. The wait is not a fixed number across the industry, so avoid anyone who quotes you a single universal figure.

A few other facts shift the reading in ways applicants often overlook:

• Immune suppression. A person taking medication that suppresses the immune system, such as after an organ transplant, is at higher risk for some skin cancers, and doctors and underwriters both treat that history more carefully. The drug itself becomes part of the file.
• Many lesions. A long list of small basal cell cancers is read as a skin-type pattern. A list in which the type changes, for example from basal cell to squamous cell, draws more attention.
• Family history. A relative with melanoma is a separate application question and a separate topic; see how family medical history affects life insurance.
• Other health. Tobacco use, build and blood pressure still count. A good skin record does not cancel a poor result elsewhere, and a modest skin history rarely overrides an excellent profile.

None of these is a verdict. They are the ordinary variables an underwriter weighs while turning a skin cancer history into a single decision.

How the application questions are usually worded

The application is where the three types meet the forms. Wording varies, so read it closely.

• Some forms ask about "cancer" without exception, so every type is listed.
• Some forms exclude certain skin cancers in the wording, for example by saying "other than basal cell skin cancer." Where an exception is stated, it applies to the types named.
• Some ask about "any abnormal growth, mole or lesion" treated or biopsied, which captures precancers and removed moles.

When the form's wording includes a type of skin cancer, list it, with the date and treatment. When the wording clearly excludes it, you answer the question that is asked. If you are uncertain whether a diagnosis counts, say so to the agent and let the insurer decide; guessing in the direction of leaving it out creates a problem later, because medical records and prescription data can reveal it. what happens if you lie on a life insurance application describes how misstatements are treated in the the two-year contestability period.

Preparing a skin cancer file

A short, accurate file helps whichever type applies:

1. A dated list of every diagnosis, biopsy and removal, with the body site.
2. The pathology report for each cancer, with the margin line and, for melanoma, the thickness and node result.
3. The treating dermatologist's name and the date of the last full skin exam.
4. The dermatologist's recommended follow-up schedule.
5. Any note stating no evidence of recurrence.
6. A list of related treatments, such as topical medication or any immune-suppressing drugs.

Then talk to an independent agent before a formal application. informal inquiries: testing an insurer's view before you apply describes how an agent can test an insurer's view without starting a record. Carriers differ a great deal on skin cancers, and on melanoma in particular, so the choice of company can matter more than the choice of policy.

When the answer is "not yet"

If a diagnosis is recent, a pending biopsy is back or treatment is not complete, the result is often a postponement. That is a wait, not a refusal; see postponed application: why insurers make you wait. Ask in writing what the insurer wants to see and when. If you need coverage in the meantime, buying life insurance while a diagnosis or test is pending describes the options and their limits.

If an insurer offers a rated policy, table ratings and flat extras explained explains how an extra premium works. Rates can be reconsidered later if your record improves; see asking for a better rate class later.

Key takeaways

• Basal cell, squamous cell and melanoma behave differently, so insurers weigh them differently; the first is often minor once treated, the third is underwritten by stage and time.
• The pathology report is the key document: margins for basal and squamous cell, thickness, ulceration and node result for melanoma.
• Regular follow-up exams with clean findings turn a recent diagnosis into a stable history.
• Recurrence at the same site is a stronger concern than a new, separate low-risk lesion, and a dated list lets an underwriter tell them apart.
• Read the application's wording on skin cancer before you answer, list what it asks for, and compare insurers because their approaches vary.